GT Biopharma, Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
GT Biopharma shows severe financial deterioration with a massive $28.7M Greenshoe Rights liability recognition driving net losses to over $30M in Q2 2025 versus $3.7M in Q2 2024. The company has negative stockholders' equity of $25.9M and zero revenues while burning cash on R&D operations.
Red Flags Detected (7)
$28.7M Greenshoe Rights liability recognized in Q2 2025 with no prior period equivalent
Stockholders' equity deficit expanded from -$1.7M to -$25.9M in 6 months
Net loss per share deteriorated dramatically from -$2.17 to -$10.92 quarterly
4 more red flags detected
Key Takeaways
Company faces potential insolvency with liabilities far exceeding assets
Greenshoe Rights liability represents major one-time or recurring financing obligation
3 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.